The data of the second phase of the Israeli anti-COVID-19 Coronavirus disease drug disclosed: the anti-COVID-19 drug cures 90% of critically ill patients within 5 days
According to Israel’s "Jerusalem Post" a few days ago, the second phase of clinical trials of the new anti-coronary pneumonia drug "EXO-CD24" developed by the team of Professor Nadir Alber from Izirov Hospital in Israel has again achieved positive results, and the critically ill patients who participated in the experiment More than 90% of them were cured and discharged within 5 days.
Due to the improvement of the Israeli epidemic before, the number of severely ill patients was small, and the second phase of the experiment was carried out in Greece. According to reports, among the 90 patients treated with EXO-CD24 in many hospitals in Greece, 93% were discharged within 5 days. It also seems to have a positive effect on patients who failed to cure quickly, and none of them required intubation or breathing. Machine treatment, and no deaths.
EXO-CD24 is a combination of CD24 protein and exosomes. CD24 can reduce the effect of the immune system, while exosomes are small lipid vesicles, which are mainly used as transport vehicles for CD24. The drug is inhaled through the nasal cavity and mainly acts on the lungs of patients. The principle is to suppress the "immune storm" that is common in severely ill patients with new coronary disease, so that the immune system can clear the virus more safely.
In September 2020, the Israeli Ministry of Health approved EXO-CD24 to start clinical trials. Of the first 30 critically ill patients, 29 were cured after 5 days of treatment, and none of them had serious side effects due to the drugs. Albert said that the purpose of the current experiment is to verify whether the drug is safe, and until now, no obvious side effects have been found in patients in the first or second phase of the experiment.
Earlier, Albert said that, compared with the traditional treatment of using steroids to suppress immune storms, EXO-CD24 is directly inhaled through the trachea to the heart of immune storms-the "lungs", and exosomal technology is used for low-dose local administration. , High safety, no adverse reactions and significant effects. At the same time, it is easy to produce and low in cost. In addition, the drug may be used to treat other acute respiratory distress syndrome (ARDS), asthma, allergic reactions, autoimmune system diseases and other problems.
It is reported that EXO-CD24 is about to start the next phase of the experiment, during which 155 critically ill patients will participate, two-thirds of which will be treated with EXO-CD24, and one-third will be given a placebo, which is expected to end by the end of this year. Albert said that the results at this stage are promising, but a controlled experiment with patients taking a placebo must be carried out.